Clinical trial
A Phase 2/3, Placebo-Controlled, Efficacy and Safety Study of Once-Weekly, Subcutaneous LY2189265 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus on Metformin
NCT00734474 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2/3, Placebo-Controlled, Efficacy and Safety Study of Once-Weekly, Subcutaneous LY2189265 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus on Metformin
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- August 31, 2008
- Completion date
- July 31, 2012
- Enrollment
- 1,202 (actual)
- Sites
- 99
Conditions
As the registry lists them; a condition with its own page is linked.